Two Sigma Advisers LP Buys New Stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Two Sigma Advisers LP purchased a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 707,555 shares of the biopharmaceutical company's stock, valued at approximately $722,000. Two Sigma Advisers LP owned 0.34% of Sangamo Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Point72 Asset Management L.P. acquired a new position in shares of Sangamo Therapeutics in the fourth quarter worth about $2,316,000. Geode Capital Management LLC lifted its position in shares of Sangamo Therapeutics by 3.4% in the 4th quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock valued at $2,257,000 after acquiring an additional 73,540 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Sangamo Therapeutics in the 4th quarter valued at approximately $1,744,000. Charles Schwab Investment Management Inc. boosted its stake in Sangamo Therapeutics by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company's stock worth $1,162,000 after purchasing an additional 35,926 shares during the period. Finally, Two Sigma Investments LP grew its position in Sangamo Therapeutics by 222.1% during the 4th quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company's stock worth $1,033,000 after purchasing an additional 698,296 shares in the last quarter. Hedge funds and other institutional investors own 56.93% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SGMO. Royal Bank of Canada restated a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Barclays dropped their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Wall Street Zen lowered Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, May 30th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday, April 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Sangamo Therapeutics currently has an average rating of "Hold" and an average target price of $4.50.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ:SGMO traded up $0.04 during midday trading on Friday, hitting $0.53. 6,280,542 shares of the stock were exchanged, compared to its average volume of 8,833,358. The company has a market capitalization of $123.58 million, a PE ratio of -0.71 and a beta of 1.46. Sangamo Therapeutics, Inc. has a 52-week low of $0.30 and a 52-week high of $3.18. The business's fifty day simple moving average is $0.62 and its two-hundred day simple moving average is $1.14.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. As a group, equities analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.